Complete Omics Inc. offers cutting-edge multiomics analysis services tailored for large cohort samples, perfectly aligning with the objectives and methodologies of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) projects. Under the guidance of our Chief Scientific Officer, Dr. Hui Zhang, who not only specializes in CPTAC-related projects but is also a founding member of this crucial task, we are uniquely positioned to advance the understanding of cancer’s molecular basis through comprehensive proteogenomic analysis. Our services leverage the latest in proteomics, genomics, and metabolomics to offer unparalleled insights into cancer biology, mirroring CPTAC’s pioneering efforts in colorectal, breast, and ovarian cancer research. By integrating our analysis with the expansive CPTAC framework—which has significantly contributed to proteogenomic characterizations, open-source resources, and the acceleration of precision oncology—we facilitate the identification of proteomic-centric subtypes, the prioritization of driver mutations, and the elucidation of cancer-relevant pathways. Our commitment to supporting the APOLLO network and the International Cancer Proteogenome Consortium (ICPC) underscores our dedication to bridging oncology research with patient care and fostering international collaboration for a global impact on cancer research and therapy.

There are several milestone papers published by our founders demonstrating our expertises and impacts on large cohort clinical sample multiomics studies. Please click on the papers below:

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell. 2016 Jul 28;166(3):755-765.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019 Oct 31;179(4):964-983.e31.

Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021 Sep 16;184(19):5031-5052.e26.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and Python scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, Tissue culture cell pellets

2, Tumor tissue chunk

3, Clinical Biopsy Samples (minimal 5 mg tissue)

4, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details.

5, FFPE blocks

6, Customized sample types (please contact us to discuss)

Complete Omics Inc. Proudly Welcomes Proteomics Luminary Dr. Hui Zhang as Chief Scientific Officer

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the…

Read more

Securing a Brighter Future: Celebrating Our Investment from Qiming Venture Partners

November 25, 2023 | BALTIMORE –  Complete Omics management team are thrilled to announce a significant milestone for our company – a recent investment by Qiming Venture Partners. This partnership…

Read more

Complete Omics Inc. Founder Qing Wang Featured on Wharton Business School’s Official Website

July 27, 2023 | BALTIMORE –  Complete Omics is proud to announce a momentous occasion for Complete Omics Inc.: our visionary founder, Qing Wang, has been featured on the prestigious…

Read more

Some of our impacts